ProfileGDS5678 / 1427385_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 78% 78% 74% 78% 80% 81% 77% 75% 79% 78% 78% 80% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.630580
GSM967853U87-EV human glioblastoma xenograft - Control 25.4522178
GSM967854U87-EV human glioblastoma xenograft - Control 35.420678
GSM967855U87-EV human glioblastoma xenograft - Control 44.910974
GSM967856U87-EV human glioblastoma xenograft - Control 55.3511878
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.4270880
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6099481
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2275577
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0337575
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.6224579
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3170378
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.4021578
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.683680
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.4673679